Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Sees Significant Increase in Short Interest

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 745 shares, an increase of 102.4% from the December 31st total of 368 shares. Based on an average daily trading volume, of 3,722 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the company are short sold. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 3,722 shares, the short-interest ratio is currently 0.2 days.Analyst Ratings ChangesA number of brokerages have recently issued reports on AAPG. Truist Financial set a $51.00 price objective on Ascentage Pharma Group International in a research report on Monday, November 24th. Oppenheimer initiated coverage on shares of Ascentage Pharma Group International in a report on Thursday, December 4th. They set an "outperform" rating and a $45.00 price target on the stock. Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They issued a "buy" rating and a $48.00 price target for the company. BTIG Research assumed coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They set a "buy" rating and a $50.00 price objective on the stock. Finally, Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a "strong-buy" rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $48.40.Read Our Latest Stock Analysis on AAPGAscentage Pharma Group International Stock PerformanceNASDAQ:AAPG opened at $25.00 on Friday. The stock's fifty day moving average is $28.49 and its 200 day moving average is $34.87. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. Ascentage Pharma Group International has a fifty-two week low of $17.09 and a fifty-two week high of $48.45. Institutional Inflows and OutflowsA number of hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International during the third quarter valued at approximately $383,000. XY Capital Ltd increased its holdings in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company's stock worth $707,000 after purchasing an additional 12,530 shares during the period. UBS Group AG raised its position in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company's stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter. ABC Arbitrage SA purchased a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth $204,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth $96,000. Ascentage Pharma Group International Company Profile (Get Free Report)Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors. Founded in 2008 by biotechnology entrepreneur Dr.Read MoreFive stocks we like better than Ascentage Pharma Group InternationalElon Taking SpaceX Public! $100 Pre-IPO Opportunity!The biggest scam in the history of gold markets is unwindingBuy This Stock at 9:30 AM on MONDAY!NEW LAW: Congress Approves Setup For Digital Dollar?Nvidia CEO Issues Bold Tesla CallThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Ascentage Pharma Group International Right Now?Before you consider Ascentage Pharma Group International, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here